Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Background: Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The ai...

Full description

Bibliographic Details
Main Authors: Cheung, Laurence, de Kraa, Rebecca, Oommen, Joyce, Chua, Grace-Alyssa, Singh, Sajla, Hughes, Anastasia M, Ferrari, Emanuela, Ford, Jette, Chiu, Sung K, Stam, Ronald W, Kees, Ursula R, Malinge, Sébastien, Kotecha, Rishi
Format: Journal Article
Language:English
Published: 2021
Subjects:
KMT2A
MLL
PER cell lines
acute lymphoblastic leukemia
carfilzomib
infant
Online Access:http://purl.org/au-research/grants/nhmrc/1142627
http://hdl.handle.net/20.500.11937/83420

Internet

http://purl.org/au-research/grants/nhmrc/1142627
http://hdl.handle.net/20.500.11937/83420

Similar Items